DrugDevCovid19

Tracking the relevant researches of CADD drug development against COVID-19

Penciclovir

ID MW HBD HBA
135398748  253.344
RB NOA Rings logP
782-1.58

Function

DrugBank ID:

DB00299


Description:

Penciclovir is a synthetic acyclic guanine derivative with antiviral activity used for the treatment of various herpes simplex virus (HSV) infections. Displaying low toxicity and good selectivity, penciclovir is a nucleoside analogue. [DrugBank]

Targets:

DNA polymerase catalytic subunit (HHV-1); Thymidine kinase () [DrugBank]

Pharmacodynamics:

Penciclovir is the active metabolite of the oral product famciclovir. The more favorable results observed with topical penciclovir versus topical acyclovir for the treatment of herpes labialis may be due to the longer intracellular half-life of penciclovir in HSV-infected cells. The activated drug inhibits the viral DNA polymerase. This impairs the ability of the virus to replicate within the cell. [DrugBank]

Structures

SMILES:

Nc1nc2c(ncn2CCC(CO)CO)c(=O)[nH]1

2D structures:  

3D structures:  

Docking in target protein

Receptor: RdRp

Docking Site: Catalytic pocket

Ligand: Penciclovir

Vina score: -5.3

Off-target analysis based on ligand similarity (Homo sapiens)

Step 1 - Target prediction for Penciclovir: SwissTargetPrediction

Tips: Click on the link to jump to the 'SwissTargetPrediction' webserver. Select the species of 'Homo sapiens', and then paste the SMILES of Penciclovir in the SMILES input box.

Step 2 - Blind docking for Penciclovir: CB-Dock

Tips: Click on the link to jump to the 'CB-Dock' webserver. Upload the structure file of target predicted by 'SwissTargetPrediction' and the 2D/3D structure file of Penciclovir to perform blind docking.